百勝中國、百濟神州、再鼎醫藥公告迴應《外國公司問責法案》
中國證監會:堅決反對一些勢力將證券監管政治化的錯誤做法。
近日,美國證監會(SEC)發佈消息,依據《外國公司問責法》認定了五家在美上市公司爲有退市風險的「相關發行人」。
中國證監會昨天(3月10日)晚間迴應稱,這是美國監管部門執行《外國公司問責法》及相關實施細則的一個正常步驟。我們此前已經多次就《外國公司問責法》的實施表明過態度。我們尊重境外監管機構爲提高上市公司財務信息質量加強對相關會計師事務所的監管,但堅決反對一些勢力將證券監管政治化的錯誤做法。我們始終堅持開放合作精神,願意通過監管合作解決美方監管部門對相關事務所開展檢查和調查問題,這也符合國際通行的做法。
近一段時間,中國證監會和財政部持續與美國公衆公司會計監督委員會(PCAOB)開展溝通對話,並取得積極進展。我們相信,雙方通過共同努力一定能夠儘快作出符合兩國法律規定和監管要求的合作安排,共同保護全球投資者合法權益,促進兩國市場健康穩定發展。
3月11日早晨,三家公司發公告迴應了該法案。百勝中國公告稱,根據該法案的現行條款,除非該法案獲修訂將本公司排除,或PCAOB能夠在規定時間內對本公司的審計師進行全面覈查,否則本公司的普通股將於2024年初從紐約證券交易所退市。百濟神州公告稱,一直在尋求解決方案以滿足《外國公司問責法案》的要求,將持續確保合規並繼續符合所有相關法律法規。再鼎醫藥稱,正在評估、設計和執行額外的業務程序和控制變更,以滿足HFCA法案的要求。
百濟神州公告:


百勝中國公告:

再鼎醫藥公告:


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.